PFE - Pfizer Takeda say four-year data support Adcetris as Hodgkin lymphoma treatment
2024-06-03 14:24:35 ET
More on Pfizer, Takeda
- Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe?
- Pfizer: Turning The Corner (Rating Upgrade)
- Pfizer: Down To A Historically Low Valuation - Is It A Buy?
- Takeda gets positive opinion from EU regulators for cTTP therapy
- GSK, Pfizer must face tens of thousands of Zantac cases in Delaware